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Abstract
Background: Antidepressant medication is commonly used to treat depression. However, many patients do not
respond to the first medication prescribed and improvements in symptoms are generally only detectable by clinicians
4–6 weeks after the medication has been initiated. As a result, there is often a long delay between the decision to
initiate an antidepressant medication and the identification of an effective treatment regimen.
Previous work has demonstrated that antidepressant medications alter subtle measures of affective cognition in
depressed patients, such as the appraisal of facial expression. Furthermore, these cognitive effects of antidepressants
are apparent early in the course of treatment and can also predict later clinical response. This trial will assess whether
an electronic test of affective cognition and symptoms (the Predicting Response to Depression Treatment Test;
PReDicT Test) can be used to guide antidepressant treatment in depressed patients and, therefore, hasten treatment
response compared to a control group of patients treated as usual.
Methods/design: The study is a randomised, two-arm, multi-centre, open-label, clinical investigation of a medical
device, the PReDicT Test. It will be conducted in five European countries (UK, France, Spain, Germany and the
Netherlands) in depressed patients who are commencing antidepressant medication. Patients will be randomised
to treatment guided by the PReDicT Test (PReDicT arm) or to Treatment as Usual (TaU arm). Patients in the TaU
arm will be treated as per current standard guidelines in their particular country. Patients in the PReDicT arm will
complete the PReDicT Test after 1 (and if necessary, 2) weeks of treatment. If the test indicates non-response to
the treatment, physicians will be advised to immediately alter the patient’s antidepressant therapy by dose escalation
or switching to another compound. The primary outcome of the study is the proportion of patients showing a clinical
response (defined as 50% or greater decrease in baseline scores of depression measured using the Quick Inventory of
Depressive Symptoms – Self-Rated questionnaire) at week 8. Health economic and acceptability data will also be
collected and analysed.
Discussion: This trial will test the clinical efficacy, cost-effectiveness and acceptability of using the novel PReDicT Test
to guide antidepressant treatment selection in depressed patients.
Trial registration: ClinicalTrials.gov, ID: NCT02790970. Registered on 30 March 2016.
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Background
Depression is a common, serious and, in some cases,
life‐threatening condition, affecting around 350 million
people globally [1]. It is associated with significant socio-
economic costs and has been predicted to become the
greatest cause of disability worldwide by 2030 [2, 3]. In
2010, it was estimated that there were approximately 30
million patients with depression in Europe, with aggre-
gated economic costs of approximately €92 billion [4].
Improvements in managing the treatment of depression
are urgently needed to improve patient outcomes, con-
tain rising healthcare costs, improve workplace product-
ivity, and help to address global economic and societal
challenges.
While a range of effective antidepressant medications
are available, it takes 4–6 weeks after starting treatment
before a physician can reliably detect whether the treat-
ment is working [5]. Additionally, more than 50% of
patients fail to respond to the first antidepressant treat-
ment that they are prescribed [6, 7]. Therefore, it often
takes several months to identify an effective antidepres-
sant treatment for a majority of patients with depression.
During this time a patient’s ability to work and function
socially may be severely impaired.
Previous work has found that antidepressant medica-
tion alters the processing of emotional information [8];
for example, by causing depressed patients to label am-
biguous facial expressions as more positive. Indeed, it
has been argued that alteration of emotional processing
bias represents one mechanism by which antidepressants
cause improved mood in patients [8]. Consistent with
this, the degree to which antidepressants induce these
changes in emotional processing early in treatment is
predictive of the later improvement in subjective symp-
toms as reported by depressed patients [9]. The PReDicT
(Predicting Response to Depression Treatment) Test
that will be used in this study has been developed from
this work. The test combines a measure of emotional
processing with the Quick Inventory of Depressive
Symptoms – Self-Rated-16 (QIDS-SR-16) questionnaire
[10]. The test has been designed to predict, after 1 week
of antidepressant treatment, whether a patient will go on
to respond to that treatment. A pilot study [11] of the
measures used in the PReDicT Test found that it accur-
ately predicted treatment response (defined as a 50% or
greater reduction in baseline score on the QIDS-SR-16
by week 6 of treatment [6]) in 74% of depressed,
primary-care patients.
The clinical opportunity provided by the early detec-
tion of antidepressant treatment response is that patients
who are predicted to not be responding after 1 week can
have their treatment altered at this time rather than
waiting 4–6 weeks as is the case with present standards
of care [5]. The current study will assess the effects of
using the PReDicT Test to guide antidepressant treat-
ment primarily in a primary-care setting. Depressed pa-
tients who are judged by their primary-care physician to
require treatment with an antidepressant medication will
be randomly assigned to have their treatment guided by
the PReDicT Test (PReDicT arm) or to receive Treat-
ment as Usual (TaU arm). Patients in the PReDicT arm
will complete the PReDicT Test after one and, if neces-
sary, 2 weeks of treatment. If the test indicates a likely
non-response after either test, then patients will have
their antidepressant treatment changed. Participants in
the TaU arm will receive standard care, with subjective
treatment response assessed after 4–6 weeks of treat-
ment. The primary outcome of the study is the propor-
tion of patients showing a response to treatment at week
8 of the study. Exploratory outcomes include assessment
of treatment response at other time points and using
alternative symptom measures.
If the PReDicT Test is successful in reducing the time
needed to identify and initiate effective antidepressant
therapy, it will be implemented routinely in primary care
provided that it is cost-effective and the technology is
acceptable for use by both patients and clinicians. Add-
itional objectives of the study will, therefore, also include
robust health economic analysis assessing cost-utility
and cost-effectiveness as well as assessment of the bar-
riers and facilitators to implementation of the PReDicT
Test into primary-care services.
Methods/design
The objectives of the study are listed in Table 1.
Study overview
The study is a randomised, two-arm, multi-centre, open-
label, clinical investigation of a medical device, the PReDicT
Test. It will be conducted in depressed patients in five
European countries (UK, France, Spain, Germany and the
Netherlands). The Standard Protocol Items: Recommenda-
tions for Interventional Trials (SPIRIT) Checklist for the
study is included as an additional file (Additional file 1) and
the SPIRIT diagram for the study is included as Appendix
1: Table 2 and Appendix 2: Table 3.
Study population
Inclusion criteria
Potential participants will be included if they meet the
following criteria:
Male or female and aged between 18 and 701 years
inclusive.
Diagnosed with a depressive episode by a physician
(either first episode or recurrent) and requiring treat-
ment with a selective serotonin reuptake inhibitor
(SSRI) medication (excluding fluoxetine due to its
long half-life).
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Prescribed an SSRI by a physician for the treatment of
depression within the 7 days prior to visit 1, but has not
yet started taking the medication.
Is intending to start SSRI treatment within 7 days of
visit 1.
Willing and able to comply with study procedures.
Able to give written informed consent and has signed
the Informed Consent Form prior to the first study-
related procedure.
Exclusion criteria
Potential participants will be excluded if they meet the
following criteria:
Previous history of mania.
Currently taking an antidepressant medication or has
stopped antidepressant treatment within 2 weeks prior
to visit 1.2
Requires immediate referral to alternative mental
health services (e.g. where patient seen in primary care
is referred to secondary-care services).
Presents to a physician with significant current suicidal
intent requiring enhanced care.
Is employed directly by the investigator or is related to
the investigator.
Currently taking part in another interventional clinical
study which, in the opinion of the investigator, is likely
to interfere with the objectives of the current study.
Recruitment
Participants will be recruited from clinical services in
the UK, France, Germany, Spain and the Netherlands.
Potential participants with symptoms of depression will
visit a physician. If a physician, using their standard
practice, decides to prescribe an SSRI medication (ex-
cluding fluoxetine) to treat their patient’s depression,
they can be considered for the study. Treatment with
fluoxetine is excluded as this drug has a long half-life
Table 1 Study objectives
Type of
objective
Objective
Primary To determine whether use of the PReDicT Test to
direct antidepressant treatment results in an
increased proportion of depressed patients showing
a response (defined as 50% or greater reduction
from baseline Quick Inventory of Depressive
Symptoms – Self-Rated-16 (QIDS) score) to
treatment at week 8 compared to TaU.
Secondary
efficacy
objective
To compare the change from baseline in QIDS
scores (i.e. treated as a continuous variable) at week
8 between depressed patients receiving treatment
directed by the PReDicT Test and those receiving
TaU
To determine whether use of the PReDicT Test to
direct antidepressant treatment results in an
increased proportion of depressed patients
showing a response to treatment at week 8
compared to TaU, where response is defined as a
decrease of 50% or more from baseline
Montgomery-Åsberg Depression Rating Scale
(MADRS) scores [10].
To determine whether use of the PReDicT Test to
direct antidepressant treatment results in an
increased proportion of depressed patients
achieving remission at week 8 compared to TaU
where remission is defined as a QIDS score of 5
or less.
To determine whether use of the PReDicT Test to
direct antidepressant treatment results in an
increased proportion of depressed patients
achieving remission at week 8 compared to TaU
where remission is defined as a MADRS score of 7
or less.
To compare the change from baseline in QIDS
score (i.e. treated as a continuous variable) at week
12 between depressed patients receiving treatment
directed by the PReDicT Test and those receiving
TaU.
To compare the change from baseline in Quick
Inventory of Depressive Symptoms – Self-Rated-16
(QIDS-SR-16) score (i.e. treated as a continuous
variable) at 24 and 48 weeks between depressed
patients receiving treatment directed by the PReDicT
Test and those receiving TaU
Health
economic
objectives
To determine the impact on societal costs and
cost-effectiveness/cost-utility of the PReDicT Test
intervention in comparison to TaU over 24 weeks and
over 48 weeks if feasible
Acceptability
and
implementation
objectives
To explore how the PReDicT Tests are used by various
stakeholders (patients, prescribing physicians and
support staff), and the impact this has on care and
care processes, in order to refine its future
implementation across different countries.
Exploratory
objectives
To compare the change from baseline in Generalised
Anxiety Disorder Questionnaire, 7-item version
(GAD-7) [11] score (i.e. treated as a continuous
variable) at week 8 between depressed patients
receiving treatment directed by the PReDicT Test and
those receiving TaU.
To compare the change from baseline on the
depression and anxiety items (analysed separately) of
the QIDS at week 8 between depressed patients
Table 1 Study objectives (Continued)
Type of
objective
Objective
receiving treatment directed by the PReDicT Test and
those receiving TaU.
To determine the change of cognitive function
(assessed using the Digit Symbol Substitution Test
(DSST) [12] ) from baseline to week 8 between
depressed patients receiving treatment directed by
the PReDicT Test and those receiving TaU.
To compare the change from baseline in self-reported
social and occupational functioning at weeks 8, 24
and 48 between depressed patients receiving
treatment directed by the PReDicT Test and those
receiving TaU.
Safety objective To obtain evidence, as required by medical devices
legislation, that the PReDicT Test is safe for use in
primary care.
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which limits the ability to rapidly switch to alternative
medications as required in the current study if non-
response is detected. The physician will provide a brief
explanation of the study and will schedule a time for a
screening and inclusion visit (see Appendix 1: Table 2)
that can be cancelled if the participant decides not to
take part in the study.
Study centres
Details of study centres are provided at https://clinical-
trials.gov/ct2/show/NCT02790970. As the exact struc-
ture of the healthcare system, and the care pathway of
depressed patients, varies by recruiting country, study
centres were selected as the closest to primary-care
settings in which antidepressant treatment is routinely
managed. In the UK, Germany, Spain and the
Netherlands this is in primary general-care settings; in
France it is located in a secondary service to which
primary-care physicians refer patients before initiating
treatment.
Study device
The PReDicT Test is a computer software application. It
is CE-marked and is categorised as a Class I medical de-
vice. The PReDicT Test comprises the QIDS-SR-16
questionnaire, a facial recognition task [12] and a propri-
etary prediction algorithm. These have been developed
and optimised to be sensitive to early changes in the
negative emotional bias associated with depression.
The PReDicT Test will be accessed on a tablet, smart-
phone or personal computer connected to the Internet
using a standard web browser. The participant will an-
swer the questions and complete the tasks that appear
on the screen. Analysis of the participant’s responses will
indicate whether a treatment has successfully altered
their emotional bias.
The PReDicT Test takes approximately 15 min to
complete. Results, indicating response or non-response
to treatment, are available immediately on completion of
the test. Test results will only be provided to the study
researcher/physician when appropriate and will not be
provided to participants.
The PReDicT Test will be accessed through an elec-
tronic, patient-reported outcomes system (ePRO) which
will also collect questionnaire data (e.g. QIDS-SR-16
score) and which will randomise participants and allow
monitoring of participant compliance both with the PRe-
DicT Test itself and with the trial procedures.
Outcome measures
A summary of the outcome measures collected and their
timings is provided in Appendix 1: Table 2.
Primary (efficacy): the primary outcome measure is
the self-rated version of the Quick Inventory of
Depressive Symptoms (QIDS-SR-16) [10]. This is
collected at week 0 (baseline) and week 8 allowing
calculation of the primary endpoint; whether the pa-
tient has shown a clinical response (defined as a
greater than 50% reduction from baseline QIDS-SR-16
score by week 8) [6].
Health economics: a bespoke Health Economics Ques-
tionnaire (HEQ) will be used to measure direct and in-
direct costs throughout the study (NB a bespoke
measure was developed as there is currently no validated
measure which captures all relevant aspects of resource
use and broader societal impacts). In addition, time dir-
ectly related to the PReDicT Test (e.g. induction time,
completing the PReDicT Test by participants, adminis-
tering/reviewing the test by clinicians) will be recorded.
The EQ-5D-5 L, a 5-dimensional, 5-level health-related
quality of life questionnaire [13] will be collected as will
the Oxford CAPabilities questionnaire-Mental Health
(OxCAP-MH) to measure broader wellbeing [14].
Acceptability and implementation: bespoke Patients
and healthcare providers Acceptability Questionnaires
(PAQ) will be completed by all patients and healthcare
providers in the study (NB these measures were devel-
oped during study development as no directly applicable
measures were available). In addition, subsamples of
patients and healthcare providers will complete bespoke
semi-structured interviews relating to the acceptability
and implementation of the PReDicT Test.
Exploratory endpoints: The Montgomery-Åsberg De-
pression Rating Scale (MADRS) [15] will be used to
assess observer-rated symptoms of depression. The Gen-
eral Anxiety Disorder Questionnaire, 7-item version
(GAD-7) [16] will be used to measure symptoms of anx-
iety in patients. The Digit Symbol Substitution Test
(DSST) [17] will be used to measure cognitive function-
ing in patients and the ‘screener’ form for the Social Ad-
justment Scale, self-report version (SAS-SR) [18] will be
used to assess quality of life.
Safety endpoints: all adverse events, adverse device
events and device deficiencies will be collected up to the
final study visit (week 8).
Study design
The study is a randomised, two-arm, multi-centre, open-
label, clinical investigation of a medical device, the PRe-
DicT Test.
The study is divided into an 8- to 10-week clinical
phase and a 40-week follow-up phase. Each participant
will be in the study for a total of up to 48–50 weeks.
During the clinical phase, participants will attend be-
tween two and four study visits, depending on their
study arm and their response to treatment. Some of
these visits may be conducted by telephone. Participants
will also complete weekly online questionnaires from
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home (see Fig. 1 and Appendix 1: Table 2 for time and
events during this phase). During the follow-up phase par-
ticipants will complete online questionnaires from home
every 4 weeks over a 40-week period (see Appendix 2:
Table 3 for time and events table).
Clinical phase: all participants will attend a screening
visit. Those meeting the study entry criteria will
complete the PReDicT Test during the visit and will be
randomised to receive either treatment directed by the
PReDicT Test (PReDicT arm) or TaU (TaU arm). Partici-
pants in the PReDicT arm will complete the PReDicT
Test again at week 1. A change to participants’ anti-
depressant treatment will be suggested to the prescribing
physician in accordance with locally appropriate guide-
lines and clinical judgement (either by dose escalation or
switching to another drug) if the PReDicT Test indicates
non-response to drug.3 In this case (i.e. the PReDicT
Test at week 1 indicates a non-response), the participant
will also complete the PReDicT Test at week 2. PReDicT
Test results will be provided to the prescribing physician
for participants in the PReDicT arm at weeks 1 and (if
necessary) week 2.
Participants in the TaU arm will complete the PRe-
DicT Test again at week 1.
PReDicT Test results will not be provided to the pre-
scribing physician for participants in the TaU arm. Any
change made to treatment by the prescribing physician
will be based only on TaU (e.g. a change in drug treatment
due to undesirable side effects or non-responsiveness
based on clinical judgement).
At week 8, all participants will undergo clinical assess-
ment of their response to treatment using questionnaires
and assessments. They will also be asked to complete a
Patient Acceptability Questionnaire (PAQ). A Health
Economics Questionnaire (HEQ) will be also completed
at weeks 0, 4 and 8.
Follow-up phase: starting at week 8, all participants
will be asked to complete three online questionnaires
every 4 weeks for 40 weeks. These questionnaires will
capture depression status and health economic data.
Two further questionnaires relating to social functioning
and wellbeing will be completed at week 24 and again at
week 48 of the study. Activities taking place during the
online follow-up phase of the study are shown in the
‘time and events’ table in Appendix 2: Table 3.
Overall trial management and monitoring will be the
responsibility of the study sponsor.
Randomisation
Randomisation is carried out by the ePRO system using an
independently validated programme.4 Study researchers
will not be blind to participant group allocation. In order
Fig. 1 Outline of trial design
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to reduce, as far as possible, the impact of expectation bias
participants will not be explicitly told which study arm they
are in, although they will be able to infer this if, for ex-
ample, their treatment is changed after 1 week. The study
cannot be blinded to a higher level as randomisation will
determine the procedures that participants must complete.
Participants will be randomised into the PReDicT arm
or the TaU arm using a 1:1 overall ratio. Randomisation
will be stratified by study country and minimised by: (1)
gender (male/female), (2) age (18–45 years and 45–70
years) and (3) baseline depression severity. Baseline de-
pression severity will be calculated by the study software
using QIDS-SR-16 scores. This will be categorised as
mild/moderate (score 6–15) and severe/very severe
(score of 16 or above).
The first 110 participants will be assigned to the PRe-
DicT arm or the TaU arm in a 1:10 ratio. The rationale
for predominantly recruiting into the TaU arm early in
the study is that the first 100 participants will be used to
further refine the algorithm used to guide treatment.
During this phase minimisation will not be used. After
this the minimisation procedure will be applied, with
minimisation being followed in 66% of cases. This will
result in a 1:1 overall ratio across the duration of the
study.
Statistical methods and data analysis
Sample size: sample size estimations suggest that 776
participants completed to week 8 are required.
The sample size was determined based on a minimum
clinically relevant effect size (i.e. the difference in effect
size between the TaU and PReDicT arms) which was set
at 10% for the primary outcome (response at 8 weeks
measured using the QIDS-SR-16). While there is no gen-
eral agreement on minimum clinically relevant effect
size, a review of the US Food and Drug Administration
(FDA) data on antidepressant randomised controlled tri-
als (RCTs) found that in RCTs of antidepressants versus
placebo a minimum of 11% difference in response was
significant and measurable [19]. In addition, during dis-
cussion with expert clinicians in the protocol develop-
ment phase an effect size of less than 10% was
considered to be clinically non-significant. The baseline
response rate in the TaU group was estimated, based on
data from a pilot study [11], at 40%. Adding the mini-
mum clinically relevant effect of guided treatment of
10% to this value results in a response rate of 50% in the
PReDicT-guided arm. Setting alpha at 0.05 and power at
80% indicates that a total sample size of 776 participants
with primary outcome data (388 per group) would be re-
quired to detect the specified minimum clinically rele-
vant difference of 10%. The expected attrition rate
across the first 8 weeks of the trial, based on data from
the pilot study, is 33%. Participants withdrawn from the
study will not be replaced (that is an intention-to-treat
analysis will be performed), thus 1158 participants will
be enrolled to ensure that 776 participants complete the
study.
Analysis of primary objective: logistic regression will be
performed to explore treatment effects on the rates of
response using an intention-to-treat approach.
Analysis of exploratory objectives: for the following
outcomes which are analysed at week 8 of the study:
MADRS, GAD-7, DSST scores, SAS-SR (screener ver-
sion) and QIDS-SR-16 (including anxiety and depression
items score), linear regression will be performed to
quantify treatment effects with a baseline measure in-
cluded as a covariate [20].
For other exploratory outcome measures, including
SAS-SR (screener version) and QIDS-SR-16, which will
be followed up monthly over the period of 1 year, multi-
level modelling will be conducted to quantify treatment
effects with ‘participant’ as a level-2 unit, treatment sta-
tus and treatment × time interactions. Baseline measure-
ment will be included in the multilevel models as a
covariate [21].
For all regression modelling, age, gender, and baseline
depression score will be included as covariates and
country influence on treatment effect estimates will also
be adjusted [22, 23]. Outcome missing value patterns
will be examined and the influence of baseline measures
and treatment allocation on missingness will investigated
to inform multiple imputation procedure under the
missing-at-random assumption.
An exploratory sensitivity analysis will test the effect
of modifying the algorithm after 110 patients have com-
pleted the study.
Analysis of health economic objectives: the main health
economic analysis will include: (1) a detailed patient-
level cost analysis of health, social care and other
broader societal costs for both the PReDicT and TaU
arms of the study and (2) an incremental within-trial
economic evaluation comparing the PReDicT arm and
the TaU arm of the study in terms of their costs and out-
comes over a 6-month follow-up period (week 0 to week
24). An optional health economic analysis may be also
conducted over the full 12-month study follow-up
period.
Analysis of acceptability and implementation objec-
tives: acceptability questionnaires will be reported using
descriptive statistics. Free text comments will be ana-
lysed thematically. Questionnaire and demographic data
will be used to guide sampling for semi-structured inter-
views performed on a subsample of patients and
clinicians.
Both the questionnaire and interview data will be used
to develop an inductive analysis of the value and imple-
mentation of the PReDicT Test.
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Analysis of safety objectives: safety data will be re-
ported using descriptive statistics.
Interim analysis: an interim analysis will be performed
when approximately 300 participants have been re-
cruited. The interim analysis will assess recruitment
rates within each country, adherence to the protocol and
safety in terms of adverse events and device deficiencies
in the two study arms. The interim analysis will also as-
sess the effect size of the difference between the PRe-
DicT arm and TaU arm on the primary outcome in
order to assess the underlying assumptions of the power
analysis and, if necessary, suggest an increased target re-
cruitment figure. The interim analysis will be carried out
and assessed by an independent Data Monitoring Com-
mittee (i.e. who are not authors of this paper or mem-
bers of the study team) who will then, if necessary, make
recommendations to the sponsor about whether alter-
ations to the study protocol are required to meet the
study objectives. The Data Monitoring Committee will
consist of an experienced psychiatric trialist, an add-
itional experienced trialist and a biostatistician.5 As all
medications used in the study are licensed antidepres-
sants, no formal stopping criteria will be used.
Discussion
This trial provides a rigorous assessment of the clinical
effectiveness as well as economic value and overall ac-
ceptability of deploying the PReDicT Test to guide anti-
depressant treatment of depressed patients. If successful,
the trial will provide evidence to support a significant al-
teration in the standard treatment of depression. Specif-
ically, it will suggest a method by which the process of
identifying and initiating effective treatments can be sub-
stantially condensed relative to current standard practice
[5]. By specifying non-responsive patients from a neuro-
psychological perspective, drawbacks of other studies of
early switching of antidepressants might be overcome
[24]. From the perspective of a depressed patient, a ra-
tional system which is able to more rapidly identify an
effective treatment for their illness may well enhance
confidence in, and improve adherence to, treatment
plans. Conceivably, the ability to personalise treatment
may also enhance the risk/benefit assessment of anti-
depressant use which has been questioned in a recent
study which pooled data from clinical trials of the non-
personalised use of antidepressants [25].
Clearly, the response of patients to antidepressant
treatment is variable, with evidence from treatment trials
indicating that separation from placebo can be detected
at the group level after 1–2 weeks of treatment [26] and
side effects commonly occurring early in the course of
treatment. The PReDicT Test is, therefore, expected to
be one of a number of potential sources of information
that clinicians may draw on when making treatment
decisions, rather than the sole arbiter of that decision.
This is reflected in the design of the current trial in
which clinicians are informed of the result of the PRe-
DicT Test but are not required to use this information
in their treatment decision if, for example, the patient
has clearly responded or developed side effects.
The PReDicT Test used in this trial has been devel-
oped as part of a translational research programme
which investigates treatment mechanism in depression,
largely utilising non-clinical human models of cognition
in controlled laboratory settings, [12]. This trial, there-
fore, also provides an important opportunity to test the
potential benefits of using recent advances in cognitive
neuroscience to improve patient care in mental health.
Trial status
Recruitment started in the UK in July 2016. Recruitment
in other countries is expected to start in late 2016/early
2017.
Endnotes
1Note an upper limit of 70 years was included as con-
sultation with primary-care clinicians during study de-
sign suggested that older patients are often started on a
reduced dose of antidepressants which is gradually ti-
trated over the course of 1–2 weeks. This pattern of
treatment would result in the PReDicT test being com-
pleted while a patient was on a potentially subtherapeu-
tic dose.
2A minimum 2 weeks absence from antidepressants
was selected to ensure that previous treatment had a
minimum effect on performance of the baseline PRe-
DicT Test.
3Note that a specific treatment algorithm was not im-
posed in this trial, rather the PReDicT Test was used to
guide treatment decisions within the context of local
practice.
4Validation refers to the computerised systems valid-
ation process followed for the ePRO system which is
designed to provide a framework for the design, develop-
ment, acquisition, validation, implementation, release,
support and maintenance of computerised systems, with
specific emphasis on applications that are within
scope of regulatory inspections, or are business crit-
ical. This process has been implemented in accord-
ance with FDA Computerised Systems Used in
Clinical Investigations May 2007 and FDA 21CFR
Part 11 Electronic Records, Electronic Signatures
1997 and any subsequent amendments.
5Members of the DMC are: DMC chair Prof. Hamish
McAllister-Williams (Newcastle University), DMC mem-
ber Dr. Peter Bower (University of Manchester) and
DMC biostatistician Dr. Rhiannon Whitaker (Whitaker
Research Ltd.).
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Table 2 Time and events table – clinical phase activities
Visit 1:
screening
and PReDicT #1
Treatment
start date
PReDicT
#2
Visit 2
(if required)
Change of dose
start datea
(if required)
PReDicT #3
(if required)
Visit 3
(if required)
Change
of medication
start dateb
(if required)
Visit 4c
Requirements for timing
of visit/event
Within 7 days
of initial
consultation
Day 0 ≥7 days
after day
0
≥ 7 days
after
changed
dose
≥ 8–10
weeks
after day
0
Preferred timing Day 0 7–9 days
after day
0
0–1 day
after
PReDicT
#2
0–1 day after
visit 2
7–9 days
after
changed
dose
0–1 day
after
PReDicT
#3
0–1 day after
visit 3
8 weeks
after day
0
Informed consent X
Entry criteria check X
Change in
antidepressant (AD)
medication agreed
Xa Xb
Review of concomitant
medication
X
Review of AEs, ADEs
and device deficiencies
X X
Assessments
PReDicT Test X X Xa
QIDS-SR-16 Xd Completed weekly, starting 7 days after day 0 Xd
Randomisation X
EQ-5D-5 L X X
HEQ X X
OxCAP-MH (UK and
Germany only)
X X
SAS-SR (screener
version)
X X
GAD-7 X X
DSST X X
MADRS X X
Patient Acceptability
Questionnaire
X
aIf PReDicT #2 outcome = non-response, physician decides if antidepressant will be changed. PReDicT #3 will be completed
bIf PReDicT #3 outcome = non-response physician decides if antidepressant will be changed
cParticipants who withdraw will be invited to complete (in order of preference): visit 4 (at 8-week time point); visit 4 online questionnaires (from home at 8-week
time point); Patient Acceptability Questionnaire (immediately); no additional data
dQIDS-SR-16 is included in the PReDicT Test
AE adverse event, ADE Adeverse Device Event, EQ-5D-5 L 5-dimensional, 5-level EuroQoL health-related quality of life questionnaire, DSST Digit Symbol Substitution
Test, GAD-7 Generalised Anxiety Disorder Questionnaire, 7-item version, HEQ Health Economics Questionnaire, OxCAP-MH Oxford CAPabilities questionnaire-Mental
Health, MADRS Montgomery-Åsberg Depression Rating Scale, QIDS Quick Inventory of Depressive Symptomatology – Self Report
Appendix 1
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Additional file
Additional file 1: PReDiCT SPIRIT Checklist v0.2 6 Jan 2017. (DOCX 49 kb)
Abbreviations
CE: Conformité Européene; DSST: Digit Symbol Substitution Test;
ePRO: Electronic patient-reported outcomes; EQ-5D-5 L: 5-dimensional, 5-level
EuroQoL health-related quality of life questionnaire; GAD-7: Generalised Anxiety
Disorder Questionnaire, 7-item version; HEQ: Health Economics Questionnaire;
MADRS: Montgomery-Åsberg Depression Rating Scale; OxCAP-MH: Oxford
CAPabilities questionnaire-Mental Health; PReDicT Test: Predicting Response to
Depression Treatment Test; QIDS-SR-16: Quick Inventory of Depressive
Symptomatology – Self Report, 16 Item Version; SAS-SR (screener
version): Social Adjustment Scale – Self-Report (screener version); SSRI: Selective
serotonin reuptake inhibitor; TaU: Treatment as Usual; UK: United Kingdom.
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Table 3 Time and events table – follow-up phase activities
Online activity Follow-up #1 Follow-
up #2
Follow-
up #3
Follow-
up #4
Follow-
up #5
Follow-
up #6
Follow-
up #7
Follow-
up #8
Follow-
up #9
Follow-up
#10
Timing of activitya Week 12 i.e. 4 weeks after visit
4
Week
16
Week
20
Week
24
Week
28
Week
32
Week
36
Week
40
Week
44
Week 48
QIDS-SR-16 X X X X X X X X X X
EQ-5D-5 L X X X X X X X X X X
HEQ X X X X X X X X X X
OxCAP-MH
(UK and Germany only)
X X
SAS-SR
(screener version)
X X
aData can be captured any time up to the due date of the next follow-up
EQ-5D-5 L 5-dimensional, 5-level EuroQoL health-related quality of life questionnaire, HEQ Health Economics Questionnaire, OxCAP-MH Oxford CAPabilities
questionnaire-Mental Health, MADRS Montgomery-Åsberg Depression Rating Scale,QIDS Quick Inventory of Depressive Symptomatology – Self Report, SAS-SR
Social Adjustment Scale, self-report version
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